Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT729 Universal Cell Injection in Refractory or Relapsed cGVHD
NCT07253259Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT729 in chronic graft-versus-host disease (cGVHD), sponsored by Grit Biotechnology. Primary endpoints: Proportion of participants experiencing dose limiting toxicity at 28 days and Incidence of adverse events at 24 months. Started Dec 2025; status: recruiting.
02
Drugs
GT729
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07253259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253259.